Cycling forward

Peritoneal Dialysis International

Volumn 26, Issue 3, 2006, Pages 306-308

  Blake, Peter G ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; ICODEXTRIN; PERITONEAL DIALYSIS FLUID; PHYSIONEAL;

AUTOMATION; BLOOD PRESSURE; BLOOD VOLUME; BODY WEIGHT; CLEARANCE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; KIDNEY FUNCTION; LIFESTYLE; NOTE; PERITONEAL DIALYSIS; PERITONEAL FLUID; PERITONITIS; PRIORITY JOURNAL; TECHNOLOGY; ULTRAFILTRATION; VASCULAR RESISTANCE;

EID: 33748430664     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600304     Document Type: Note

References (15)

1. Guo A, Mujais S. Patient and technique survival on peritoneal dialysis in the United States: evaluation in large incident cohorts. Kidney Int Suppl 2003; 88:S3-12.
2. Rodriguez-Carmona A, Perez Fontan M. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int 2002; 22:705-13.
3. Huffnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14:1224-8.
4. Rippe B, Levin L. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000; 57:2546-56.
5. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862-71.
6. Wolfson M, Piraino B, Hamburger J, Morton AR, for the Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-65.
7. Jeloka TK, Ersoy FF, Yavuz M, Sahu KM, Çamsari T, Utas C, et al.What is the optimal dwell time for maximizing ultrafiltration with icodextrin exchange in automated peritoneal dialysis patients? Perit Dial Int 2006; 26:336-40.
8. Moberly JB, Mujais S, Gehr T, Hamburger R, Sprague S, Kucharski A, et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl 2002; 81: S23-33.
9. Finkelstein F, Healy H, Abu Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546-56.
10. Cueto-Manzano AM, Rojas-Campos E, Martinez-Ramirez HR, Valera-González I, Medina M, Monteón F, et al. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis? Perit Dial Int 2006; 26:341-8.
11. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl Med 1990; 323:236-41.
12. Selby NM, Fonseca S, Hulme L, Fluck RJ,Taal MW, McIntyre CW. Hypertonic glucose based peritoneal dialysis is associated with higher blood pressure and adverse hemodynamics as compared with icodextrin. Nephrol Dial Transplant 2005; 20:1848-53.
13. Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Automated peritoneal dialysis has significant effects on systemic hemodynamics. Perit Dial Int 2006; 26: 328-35.
14. De Fijter CW, Oe L, Nauta JJ, van der Meulen J, Verbrugh HA, Donker AJ, et al. Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis. Ann Intern Med 1994; 120:264-71.
15. Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H, et al. A prospective randomized multicenter study comparing CAPD and APD treatment. Perit Dial Int 1999; 19:526-33.